Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Kazia Therapeutics Limited announces a public offering priced at up to $120 million, aiming to raise approximately $40 million from the sale of securities. The offering includes American Depositary Shares and warrants.
PUBLIC · KZIAAug 28, 2026•about 4 hours ago
Amount Raised
$40 Million
Round Type
Post-IPO Equity
SydneyBiotechnologyHealth Care
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, has announced a priced public offering. The offering includes American Depositary Shares and Series A and B Warrants. The expected gross proceeds from the sale are approximately $40 million. These funds will be used to support its ongoing development of cancer therapies.
Company Information
Company
Kazia Therapeutics
Location
Level 24, Three International Towers
Sydney, New South Wales, Australia
About
Kazia Therapeutics is a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need. The company focuses on innovative drug development and is based in Sydney, Australia.
Don't miss Kazia Therapeutics's next move
Get an email the moment Kazia Therapeutics raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
2 contacts
Verified contactsMichael F., Program Director hidden
Predictive Intelligence
Strategic
ML-powered predictions for Kazia Therapeutics's next move
SydneyBiotechnologyHealth Care